Value of the XXXX suppression test in the diagnosis of @entity1911 .

@entity1 @entity101 @entity1911 @entity5 @entity2922 @entity1338 @entity2661 @entity1063
The clinical value of a @entity1338 suppression test was assessed in three different groups: I. 14 normotensive, healthy @entity1 : II. 34 @entity1 with "neurogenic" @entity101 : III. 10 @entity1 with @entity1911 confirmed at operation. After @entity1338 (300 mg by mouth) blood pressure (BP) and circulating plasma @entity2661 (CA) were reduced in groups I and II. The maximum fall in mean BP was 25/9 mmHg in group I and 43/24 mmHg in group II; the corresponding fall in @entity1 with @entity1911 was 19/0 mmHg. The mean concentrations of circulating @entity1063 (NA) were significantly reduced in groups I and II, maximum suppression occurring 2-3 h after giving @entity1338 . In group I the mean reductions in NA were from 1.3 (SEM 0.2) to 0.6 (0.06) nmol/l (p less than 0.01), and in group II from 2.6 (0.3) to 0.7 (0.05 nmol/l (p less than 0.2); plasma concentrations of A were very low (less than 0.01 nmol/l) in both groups, and remained unchanged throughout the test. In contrast, in the 10 @entity1 with @entity1911 the mean basal plasma CA concentrations exceeded our upper reference limit NA 7.7 (2.2 and A 4.0 (1.7 nmol/l), and remained high or even rose during the test. Four @entity1 in this group with only marginally elevated basal plasma CA showed the same pattern of response during @entity1338 administration. After successful removal of the @entity2922 -secreting @entity5 all @entity1 achieved a normal BP. The plasma CA was suppressed into the normal range when the @entity1338 test was repeated 1-2 weeks postoperatively. No serious adverse effects were observed.(ABSTRACT TRUNCATED AT 250 WORDS)
